Sentences with phrase «hypoactive sexual desire disorder»

Here's a quick summary of what happened: Sprout is a Raleigh, N.C. - based developer of a drug intended to treat hypoactive sexual desire disorder — a persistent lack of libido — in pre-menopausal women.

The drug, flibanserin or «Addyi», treats a condition called hypoactive sexual desire disorder (HSDD), which can cause chronic low desires to have sex in women.

Flibanserin, marketed by Valeant as Addyi, was approved by the U.S. Food and Drug Administration (FDA) in 2015 to treat premenopausal women with hypoactive sexual desire disorder (HSDD).

The diagnosis female sexual dysfunction disorder covers four conditions: lack of libido, known as hypoactive sexual desire disorder; lack of sensitivity or ability to be aroused, called female sexual arousal disorder; inability to have an orgasm, known as female orgasmic disorder; and pain during sex — which itself is divided into a number of categories.

But while the U.S. Food and Drug Administration has approved more than two dozen drugs targeting a range of male sexual matters, pharma has turned a cold shoulder to female dysfunction, despite the prevalence of conditions like hypoactive sexual desire disorder, a chronic disinterest in sex estimated to affect 8 to 14 percent of American women ages 20 to 49.

Many women — some studies estimate this number is as high as one - third of all adult women — have a condition known as female hypoactive sexual desire disorder (HSDD).

The other seven suffered from hypoactive sexual desire disorder.

Diagnoses include hypoactive sexual desire disorder, sexual aversion disorder, sexual arousal disorder, orgasmic disorder among others.

In August, the FDA approved Addyi, the first drug authorized to treat hypoactive sexual desire disorder (HSDD), or lack of libido.

The drug treats a condition called hypoactive sexual desire disorder (HSDD), which can cause chronic low desires to have sex in women.

Perhaps men with hypoactive sexual desire disorder couldn't feel desire because their brains were keeping their emotions bottled up.

The scientists, led by Professor Andrea Fagiolini, took recruited 38 men who had been attending the Urology Department of the University of Siena following a diagnosis of hypoactive sexual desire disorder or sexual arousal disorder — both conditions which are characterised by a lack of interest in sex.

Dr. Ian Kerner will discuss the latest science - based research informing the treatment of common DSM - 5 sexual issues such as female sexual interest and arousal disorder (FSIAD), male hypoactive sexual desire disorder (HSDD), erectile disorder (ED), premature ejaculation (PE), female orgasmic disorder (FOD), and problematic sexual behaviors such as excessive use of internet pornography.

The FDA has twice rejected flibanserin, sometimes touted as a «female Viagra,» first when Boehringer Ingelheim pitched it in 2010 and then again in 2013 after tiny Sprout landed rights to the drug and then mounted its own campaign for an approval for hypoactive sexual desire disorder in premenopausal women.

The company said it would instead focus on educating doctors about the drug and the condition it treats, hypoactive sexual desire disorder.

The drug was approved to treat hypoactive sexual desire disorder, or HSDD.

Hypoactive sexual desire disorder (HSDD), on the other hand, is a deficiency or absence of sexual fantasies and desire causing marked distress or interpersonal difficulty.

The drug is intended to treat hypoactive sexual desire disorder (HSDD)-- a persistent lack of libido — in premenopausal women.

Your interest in sex may diminish (low libido or hypoactive sexual desire disorder, HSSD) and you may develop a dry vagina, so that intercourse is irritating (dyspareunia).